Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$14.50 – $19.92
54% from low
Sector
Biotechnology
P/S (TTM)
4.7
PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. It operates through the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Company and Others. The Internal segment focuses on immunological, fibrotic, and lymphatic system mechanisms. The Controlled Founded Entities segment is composed of the group’s subsidiaries that are currently consolidated operational subsidiaries that either have or have plans to hire independent management teams and currently have already raised, or are currently in the process of raising, third-party dilutive capital. The Non-Controlled Founded Entities segment includes companies wherein the group no longer holds majority voting control as a shareholder and no longer has the right to elect a majority of the members of the subsidiaries’ Board of Directors. The Parent Company and Other segment represents activities that are not directly attributable to the operating segments, such as the activities of the parent, corporate support functions and certain research and development support functions that are not directly attributable to a strategic business segment as well as the elimination of intercompany transactions. The company was founded by Robert S. Langer Jr., Bennett M. Shapiro, and Daphne Zohar on May 8, 2015 and is headquartered in Boston, MA.
puretechhealth.comNo one on the platform currently holds PRTC.
No tracked institution reports a position in PRTC as of their last filing.
No one on the platform has traded PRTC yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | -3.5% | -11.0% | ||||
| Profit Margin % | -2355.4% | -1247.2% | 206.4% | |||
| Free Cash Flow Margin % | -1831.6% | -3620.9% | -3686.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $50M | +1237.8% | $-6.47 | $-6.47–$-6.47 | — | 1 |
| 2027 | $228M | +361.0% | $-6.93 | $-6.93–$-6.93 | — | 1 |
| 2028 | $474M | +107.6% | $4.08 | $4.08–$4.08 | 4.3× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-04-29 | $-1.94 | $-26.90 | -1286.6% |
| 2025-08-28 | $-2.04 | $-1.90 | +6.9% |
| 2025-04-30 | $-2.83 | $3.60 | +227.2% |
| 2024-08-28 | $-3.03 | $-1.50 | +50.5% |
| 2024-04-25 | $-3.25 | $-1.50 | +53.8% |
| 2023-08-29 | $-0.03 | $-0.90 | -2900.0% |
| 2023-04-28 | $0.34 | $-0.78 | -329.4% |
| 2022-08-25 | $-2.75 | $-1.00 | +63.6% |
| $201M |
| — |
| KROSKeros Therapeutics, Inc. | $11.17 | -0.36% | $357M | — |
| SLNSilence Therapeutics plc | $12.46 | -4.59% | $589M | — |
Source: Financial Modeling Prep · peers by sector/industry
$PRTC .L ✅ UK London Stock Market (NOT USA) - Healthcare - Small Cap Analysts: 2x buy rating 👨🔬 Intrinsic Value Potential: Undervalued 💎 Analysts Price Target: £2.40 - £5.08 (83% - 288% above Price) 🌟 Range (52w) £1.04 - £1.48 💰 NEWSDESK (last recent article) 📰 https://uk.finance.yahoo.com/news/puretech-highlights-seaport-progress-glyphago-071558299.html Yahoo Reference: https://uk.finance.yahoo.com/quote/PRTC.L/
View on StockTwits ↗
@ChadTrades3 I bought this about 5 years ago for around $52/share and this board has been completely dead the entire time. Possibly because no matter what $PRTC and its entities accomplish, the stock is perpetually stuck in purgatory. It never, ever, ever breaks $20.
View on StockTwits ↗
$PRTC has announced that its founded entity, closely held Seaport Therapeutics, has reported positive proof of concept topline data from portions of its ongoing Phase 1 proof-of-concept clinical trial evaluating GlyphAgo (SPT-320 or Glyph Agomelatine) in generalized anxiety disorder (GAD). https://biotuesdays.com/2026/04/02/puretechs-seaport-reports-positive-data-from-trial-of-glyphago-in-gad/
View on StockTwits ↗
$PRTC (+3.6% pre) PureTech publishes phase 2b trial results for lung fibrosis drug https://ooc.bz/l/97914
View on StockTwits ↗
$PRTC This ticker is entering a stage where execution quality will overshadow headline narratives. Cost discipline must coexist with targeted investment. Smart capital allocation could unlock optionality not yet reflected. The thesis improves only as operational proof accumulates.
View on StockTwits ↗$PRTC has announced the appointment of Robert Lyne as chief executive officer (CEO), and member of the board of directors, effective immediately https://biotuesdays.com/2025/12/18/puretech-appoints-robert-lyne-as-ceo/
View on StockTwits ↗
$PRTC (-8.1% pre) PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis https://ooc.bz/l/86630
View on StockTwits ↗
$PRTC (-5.1%): PureTech Health advances deupirfenidone toward pivotal Phase 3 in idiopathic pulmonary fibrosis https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20251208051736PRTC&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
View on StockTwits ↗$PRTC Current Stock Price: $17.10 No options data available.
View on StockTwits ↗
$PRTC's hub-and-spoke model spins out mature assets (Seaport, Gallop, Celea) to attract external capital, reducing parent R&D burn while retaining equity & royalties. This extends cash runway past 2028 and shifts funding risk to VCs. 🧬 #BiotechStrategy
View on StockTwits ↗
$PRTC Great piece that accurately captures PRTC's current position. So if you want to refresh your understanding of PRTC or learn about PRTC for the first time, this is essential reading. https://beyondspx.com/quote/PRTC/analysis/puretech-health-unlocking-value-through-de-risked-innovation-and-strategic-spin-outs-prtc
View on StockTwits ↗
$PRTC Puretech Founded Entity Seaport Therapeutics Doses First Participant In Phase 1 Study Of Glyphago SPT-320 Oral Prodrug Of Agomelatine For Generalized Anxiety Disorder
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.